# Phibro Animal Health Corp: financial statements, quarterly

PAHC · Nasdaq · CIK 1069899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/pahc.md) · [Financials](/companies/pahc/financials.md) · [Filings](/companies/pahc/filings.md) · [Insiders](/companies/pahc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pahc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [231](/filings/0001558370-24-014644.md) | [250](/filings/0001558370-25-000659.md) | [263](/filings/0001558370-25-006746.md) | [273 d](/filings/0001104659-26-101493.md) | [260](/filings/0001104659-25-107001.md) | [309](/filings/0001104659-26-010317.md) | [348](/filings/0001104659-26-056280.md) | [379 d](/filings/0001104659-26-101493.md) | [364](/filings/0001104659-25-107001.md) | [374](/filings/0001104659-26-010317.md) | [384](/filings/0001104659-26-056280.md) | [397 d](/filings/0001104659-26-101493.md) |
| Cost of revenue | $m | [164](/filings/0001558370-24-014644.md) | [171](/filings/0001558370-25-000659.md) | [184](/filings/0001558370-25-006746.md) | [186 d](/filings/0001104659-26-101493.md) | [177](/filings/0001104659-25-107001.md) | [207](/filings/0001104659-26-010317.md) | [243](/filings/0001104659-26-056280.md) | [269 d](/filings/0001104659-26-101493.md) | [244](/filings/0001104659-25-107001.md) | [241](/filings/0001104659-26-010317.md) | [258](/filings/0001104659-26-056280.md) | [262 d](/filings/0001104659-26-101493.md) |
| Gross profit | $m | [67.7](/filings/0001558370-24-014644.md) | [78.6](/filings/0001558370-25-000659.md) | [79.6](/filings/0001558370-25-006746.md) | [87.2 d](/filings/0001104659-26-101493.md) | [83.5](/filings/0001104659-25-107001.md) | [102](/filings/0001104659-26-010317.md) | [105](/filings/0001104659-26-056280.md) | [110 d](/filings/0001104659-26-101493.md) | [120](/filings/0001104659-25-107001.md) | [133](/filings/0001104659-26-010317.md) | [126](/filings/0001104659-26-056280.md) | [134 d](/filings/0001104659-26-101493.md) |
| Selling, general and administrative | $m | [68.5](/filings/0001558370-24-014644.md) | [62.9](/filings/0001558370-25-000659.md) | [59.7](/filings/0001558370-25-006746.md) | [68.7 d](/filings/0001104659-26-101493.md) | [65.8](/filings/0001104659-25-107001.md) | [76.3](/filings/0001104659-26-010317.md) | [71.1](/filings/0001104659-26-056280.md) | [76.3 d](/filings/0001104659-26-101493.md) | [68.5](/filings/0001104659-25-107001.md) | [82.3](/filings/0001104659-26-010317.md) | [81.0](/filings/0001104659-26-056280.md) | [86.2 d](/filings/0001104659-26-101493.md) |
| Operating income | $m | [(0.7)](/filings/0001558370-24-014644.md) | [15.7](/filings/0001558370-25-000659.md) | [19.9](/filings/0001558370-25-006746.md) | [18.4 d](/filings/0001104659-26-101493.md) | [17.7](/filings/0001104659-25-107001.md) | [25.5](/filings/0001104659-26-010317.md) | [33.5](/filings/0001104659-26-056280.md) | [33.7 d](/filings/0001104659-26-101493.md) | [51.3](/filings/0001104659-25-107001.md) | [50.3](/filings/0001104659-26-010317.md) | [44.7](/filings/0001104659-26-056280.md) | [48.2 d](/filings/0001104659-26-101493.md) |
| Interest expense | $m | [5.6](/filings/0001558370-23-018287.md) | [5.7](/filings/0001558370-24-000859.md) | [5.6](/filings/0001558370-24-007340.md) | [6.0 d](/filings/0001104659-26-101493.md) | [8.8](/filings/0001104659-25-107001.md) | [9.8](/filings/0001104659-26-010317.md) | [9.7](/filings/0001104659-26-056280.md) | [9.0 d](/filings/0001104659-26-101493.md) | [12.5](/filings/0001104659-25-107001.md) | [12.5](/filings/0001104659-26-010317.md) | [10.7](/filings/0001104659-26-056280.md) | [10.7 d](/filings/0001104659-26-101493.md) |
| Income tax | $m | [(4.0)](/filings/0001558370-24-014644.md) | [2.3](/filings/0001558370-25-000659.md) | [4.5](/filings/0001558370-25-006746.md) | [5.7 d](/filings/0001104659-26-101493.md) | [2.6](/filings/0001104659-25-107001.md) | [1.7](/filings/0001104659-26-010317.md) | [8.8](/filings/0001104659-26-056280.md) | [6.6 d](/filings/0001104659-26-101493.md) | [9.7](/filings/0001104659-25-107001.md) | [9.0](/filings/0001104659-26-010317.md) | [8.3](/filings/0001104659-26-056280.md) | [10.6 d](/filings/0001104659-26-101493.md) |
| Net income | $m | [(8.0)](/filings/0001558370-24-014644.md) | [1.3](/filings/0001558370-25-000659.md) | [8.4](/filings/0001558370-25-006746.md) | [0.8 d](/filings/0001104659-26-101493.md) | [7.0](/filings/0001104659-25-107001.md) | [3.2](/filings/0001104659-26-010317.md) | [20.9](/filings/0001104659-26-056280.md) | [17.2 d](/filings/0001104659-26-101493.md) | [26.5](/filings/0001104659-25-107001.md) | [27.5](/filings/0001104659-26-010317.md) | [24.0](/filings/0001104659-26-056280.md) | [21.7 d](/filings/0001104659-26-101493.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001558370-24-014644.md) | [0.03](/filings/0001558370-25-000659.md) | [0.21](/filings/0001558370-25-006746.md) | not reported | [0.17](/filings/0001104659-25-107001.md) | [0.08](/filings/0001104659-26-010317.md) | [0.51](/filings/0001104659-26-056280.md) | not reported | [0.65](/filings/0001104659-25-107001.md) | [0.67](/filings/0001104659-26-010317.md) | [0.59](/filings/0001104659-26-056280.md) | not reported |
| Basic EPS | $ per share | [(0.20)](/filings/0001558370-24-014644.md) | [0.03](/filings/0001558370-25-000659.md) | [0.21](/filings/0001558370-25-006746.md) | not reported | [0.17](/filings/0001104659-25-107001.md) | [0.08](/filings/0001104659-26-010317.md) | [0.52](/filings/0001104659-26-056280.md) | not reported | [0.65](/filings/0001104659-25-107001.md) | [0.68](/filings/0001104659-26-010317.md) | [0.59](/filings/0001104659-26-056280.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [43.2](/filings/0001558370-23-018287.md) | [33.0](/filings/0001558370-24-000859.md) | [50.2](/filings/0001558370-24-007340.md) | [70.6](/filings/0001558370-25-011776.md) | [51.8](/filings/0001558370-24-014644.md) | [67.1](/filings/0001558370-25-000659.md) | [60.4](/filings/0001558370-25-006746.md) | [68.0](/filings/0001104659-26-101493.md) | [72.8](/filings/0001104659-25-107001.md) | [55.5](/filings/0001104659-26-010317.md) | [54.9](/filings/0001104659-26-056280.md) | [61.4](/filings/0001104659-26-101493.md) |
| Current assets | $m | [584](/filings/0001558370-23-018287.md) | [587](/filings/0001558370-24-000859.md) | [597](/filings/0001558370-24-007340.md) | [601](/filings/0001558370-25-011776.md) | [571](/filings/0001558370-24-014644.md) | [746](/filings/0001558370-25-000659.md) | [776](/filings/0001558370-25-006746.md) | [811](/filings/0001104659-26-101493.md) | [836](/filings/0001104659-25-107001.md) | [862](/filings/0001104659-26-010317.md) | [894](/filings/0001104659-26-056280.md) | [936](/filings/0001104659-26-101493.md) |
| Total assets | $m | [965](/filings/0001558370-23-018287.md) | [973](/filings/0001558370-24-000859.md) | [979](/filings/0001558370-24-007340.md) | [982](/filings/0001558370-25-011776.md) | [966](/filings/0001558370-24-014644.md) | [1,286](/filings/0001558370-25-000659.md) | [1,317](/filings/0001558370-25-006746.md) | [1,361](/filings/0001104659-26-101493.md) | [1,386](/filings/0001104659-25-107001.md) | [1,406](/filings/0001104659-26-010317.md) | [1,445](/filings/0001104659-26-056280.md) | [1,501](/filings/0001104659-26-101493.md) |
| Current liabilities | $m | [172](/filings/0001558370-23-018287.md) | [188](/filings/0001558370-24-000859.md) | [189](/filings/0001558370-24-007340.md) | [204](/filings/0001558370-25-011776.md) | [177](/filings/0001558370-24-014644.md) | [233](/filings/0001558370-25-000659.md) | [266](/filings/0001558370-25-006746.md) | [293](/filings/0001104659-26-101493.md) | [270](/filings/0001104659-25-107001.md) | [282](/filings/0001104659-26-010317.md) | [282](/filings/0001104659-26-056280.md) | [316](/filings/0001104659-26-101493.md) |
| Total liabilities | $m | [691](/filings/0001558370-23-018287.md) | [702](/filings/0001558370-24-000859.md) | [709](/filings/0001558370-24-007340.md) | [726](/filings/0001558370-25-011776.md) | [708](/filings/0001558370-24-014644.md) | [1,039](/filings/0001558370-25-000659.md) | [1,051](/filings/0001558370-25-006746.md) | [1,075](/filings/0001104659-26-101493.md) | [1,074](/filings/0001104659-25-107001.md) | [1,073](/filings/0001104659-26-010317.md) | [1,083](/filings/0001104659-26-056280.md) | [1,116](/filings/0001104659-26-101493.md) |
| Long-term debt | $m | [305](/filings/0001558370-23-018287.md) | [298](/filings/0001558370-24-000859.md) | [291](/filings/0001558370-24-007340.md) | [282](/filings/0001558370-25-006746.md) | [288](/filings/0001558370-24-014644.md) | [623](/filings/0001558370-25-000659.md) | [619](/filings/0001558370-25-006746.md) | [615](/filings/0001104659-26-056280.md) | [610](/filings/0001104659-25-107001.md) | [604](/filings/0001104659-26-010317.md) | [598](/filings/0001104659-26-056280.md) | not reported |
| Current portion of debt | $m | [24.2](/filings/0001558370-23-018287.md) | [26.0](/filings/0001558370-24-000859.md) | [29.8](/filings/0001558370-24-007340.md) | [29.8](/filings/0001558370-25-006746.md) | [7.5](/filings/0001558370-24-014644.md) | [16.3](/filings/0001558370-25-000659.md) | [16.3](/filings/0001558370-25-006746.md) | [16.3](/filings/0001104659-26-056280.md) | [18.4](/filings/0001104659-25-107001.md) | [20.6](/filings/0001104659-26-010317.md) | [22.8](/filings/0001104659-26-056280.md) | not reported |
| Short-term borrowings | $m | not reported | not reported | [1.9](/filings/0001558370-24-007340.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [273](/filings/0001558370-23-018287.md) | [271](/filings/0001558370-24-000859.md) | [270](/filings/0001558370-24-007340.md) | [257](/filings/0001558370-25-011776.md) | [259](/filings/0001558370-24-014644.md) | [247](/filings/0001558370-25-000659.md) | [266](/filings/0001558370-25-006746.md) | [286](/filings/0001104659-26-101493.md) | [312](/filings/0001104659-25-107001.md) | [332](/filings/0001104659-26-010317.md) | [362](/filings/0001104659-26-056280.md) | [385](/filings/0001104659-26-101493.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [16.2](/filings/0001558370-24-014644.md) | [31.6 d](/filings/0001558370-25-000659.md) | [11.4 d](/filings/0001558370-25-006746.md) | [28.4 d](/filings/0001104659-26-101493.md) | [12.6](/filings/0001104659-25-107001.md) | [3.1 d](/filings/0001104659-26-010317.md) | [43.2 d](/filings/0001104659-26-056280.md) | [21.3 d](/filings/0001104659-26-101493.md) | [9.3](/filings/0001104659-25-107001.md) | [19.4 d](/filings/0001104659-26-010317.md) | [16.2 d](/filings/0001104659-26-056280.md) | [24.1 d](/filings/0001104659-26-101493.md) |
| Capital expenditure | $m | [7.5](/filings/0001558370-24-014644.md) | [11.0 d](/filings/0001558370-25-000659.md) | [9.7 d](/filings/0001558370-25-006746.md) | [13.1 d](/filings/0001104659-26-101493.md) | [9.6](/filings/0001104659-25-107001.md) | [7.8 d](/filings/0001104659-26-010317.md) | [7.7 d](/filings/0001104659-26-056280.md) | [13.1 d](/filings/0001104659-26-101493.md) | [13.8](/filings/0001104659-25-107001.md) | [11.1 d](/filings/0001104659-26-010317.md) | [15.3 d](/filings/0001104659-26-056280.md) | [18.9 d](/filings/0001104659-26-101493.md) |
| Dividends paid | $m | [4.9](/filings/0001558370-24-014644.md) | [4.9 d](/filings/0001558370-25-000659.md) | [4.9 d](/filings/0001558370-25-006746.md) | [4.9 d](/filings/0001104659-26-101493.md) | [4.9](/filings/0001104659-25-107001.md) | [4.9 d](/filings/0001104659-26-010317.md) | [4.9 d](/filings/0001104659-26-056280.md) | [4.9 d](/filings/0001104659-26-101493.md) | [4.9](/filings/0001104659-25-107001.md) | [4.9 d](/filings/0001104659-26-010317.md) | [4.9 d](/filings/0001104659-26-056280.md) | [4.9 d](/filings/0001104659-26-101493.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.5](/filings/0001558370-23-018287.md) | [40.5](/filings/0001558370-24-000859.md) | [40.5](/filings/0001558370-24-007340.md) | [40.5](/filings/0001558370-24-014644.md) | [40.5](/filings/0001558370-25-000659.md) | [40.5](/filings/0001558370-25-006746.md) | [40.6](/filings/0001104659-25-107001.md) | [40.7](/filings/0001104659-26-010317.md) | [40.7](/filings/0001104659-26-056280.md) | [40.9](/filings/0001104659-25-107001.md) | [41.0](/filings/0001104659-26-010317.md) | [41.0](/filings/0001104659-26-056280.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.